Marinus Pharmaceuticals Inc (NAS:MRNS)
$ 1.485 0.065 (4.58%) Market Cap: 81.58 Mil Enterprise Value: 39.96 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 38/100

Marinus Pharmaceuticals Inc Presenting at UBS Global Healthcare Virtual Conference Transcript

May 24, 2021 / 12:00PM GMT
Release Date Price: $17.31 (+3.28%)
Colin Nigel Bristow
UBS Investment Bank, Research Division - Analyst

So good morning, and thank you, everyone, for joining the Virtual UBS Healthcare conference. I'm Colin Bristow, I'm one of the biotech analysts here at UBS. And it's my pleasure to have Scott Braunstein, CEO of Marinus Pharmaceuticals with me today, along with Steven Pfanstiel, CFO of Marinus. Scott and Steven, thank you for joining us today.

So before we start, if anyone has a question, there's a raise your hand function available to you or feel free to e-mail me at [email protected], and I can try and field the question for you.

Questions & Answers

Colin Nigel Bristow
UBS Investment Bank, Research Division - Analyst

So to get off with some questions, maybe a good starting point for those who are less familiar with the story is if you could give us a quick rundown of ganaxolone and each of the development programs?

Scott N. Braunstein
Marinus Pharmaceuticals, Inc. - CEO, President & Director

Sure, Colin. Thanks for

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot